Intracellular interactions of umeclidinium and vilanterol in human airway smooth muscle
Nooreen Shaikh,1,2 Malcolm Johnson,3 David A Hall,4 Kian Fan Chung,1,2 John H Riley,3 Sally Worsley,5 Pankaj K Bhavsar1,2 1Experimental Studies, National Heart and Lung Institute, Imperial College London, 2Biomedical Research Unit, Royal Brompton and Harefield NHS Trust, London, 3Respiratory Global...
Main Authors: | Shaikh N, Johnson M, Hall DA, Chung KF, Riley JH, Worsley S, Bhavsar PK |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-06-01
|
Series: | International Journal of COPD |
Subjects: | |
Online Access: | https://www.dovepress.com/intracellular-interactions-of-umeclidinium-and-vilanterol-in-human-air-peer-reviewed-article-COPD |
Similar Items
-
Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol
by: Singh D, et al.
Published: (2016-06-01) -
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
by: Nicola C. Day, et al.
Published: (2020-06-01) -
Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study
by: Kerwin EM, et al.
Published: (2017-02-01) -
Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial
by: François Maltais, et al.
Published: (2019-10-01) -
Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol
by: Molino A, et al.
Published: (2018-06-01)